Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial.

Abstract:

BACKGROUND:Temporal muscle thickness (TMT) was described as a surrogate marker of skeletal muscle mass. This study aimed to evaluate the prognostic relevance of TMT in patients with progressive glioblastoma. METHODS:TMT was analyzed on cranial MR images of 596 patients with progression of glioblastoma after radiochemotherapy enrolled in the European Organisation for Research and Treatment of Cancer 26101 trial. An optimal TMT cutoff for overall survival (OS) and progression-free survival (PFS) was defined in the training cohort (n = 260, phase II). Patients were grouped as "below" or "above" the TMT cutoff and associations with OS and PFS were tested using the Cox model adjusted for important risk factors. Findings were validated in a test cohort (n = 308, phase III). RESULTS:An optimal baseline TMT cutoff of 7.2 mm was obtained in the training cohort for both OS and PFS (area under the curve = 0.64). Univariate analyses estimated a hazard ratio (HR) of 0.54 (95% CI: 0.42, 0.70; P < 0.0001) for OS and an HR of 0.49 (95% CI: 0.38, 0.64; P < 0.0001) for PFS for the comparison of training cohort patients above versus below the TMT cutoff. Similar results were obtained in Cox models adjusted for important risk factors with relevance in the trial for OS (HR, 0.54; 95% CI: 0.41, 0.70; P < 0.0001) and PFS (HR, 0.47; 95% CI: 0.36, 0.61; P < 0.0001). Results were confirmed in the validation cohort. CONCLUSION:Reduced TMT is an independent negative prognostic parameter in patients with progressive glioblastoma and may help to facilitate patient management by supporting patient stratification for therapeutic interventions or clinical trials.

journal_name

Neuro Oncol

journal_title

Neuro-oncology

authors

Furtner J,Genbrugge E,Gorlia T,Bendszus M,Nowosielski M,Golfinopoulos V,Weller M,van den Bent MJ,Wick W,Preusser M

doi

10.1093/neuonc/noz131

subject

Has Abstract

pub_date

2019-12-17 00:00:00

pages

1587-1594

issue

12

eissn

1522-8517

issn

1523-5866

pii

5542781

journal_volume

21

pub_type

杂志文章,随机对照试验
  • The molecular profile of microglia under the influence of glioma.

    abstract::Microglia, which contribute substantially to the tumor mass of glioblastoma, have been shown to play an important role in glioma growth and invasion. While a large number of experimental studies on functional attributes of microglia in glioma provide evidence for their tumor-supporting roles, there also exist hints in...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nos116

    authors: Li W,Graeber MB

    更新日期:2012-08-01 00:00:00

  • Radiation-induced cognitive toxicity: pathophysiology and interventions to reduce toxicity in adults.

    abstract::Radiotherapy is ubiquitous in the treatment of patients with both primary brain tumors as well as disease which is metastatic to the brain. This therapy is not without cost, however, as cognitive decline is frequently associated with cranial radiation, particularly with whole brain radiotherapy (WBRT). The precise mec...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nox195

    authors: Wilke C,Grosshans D,Duman J,Brown P,Li J

    更新日期:2018-04-09 00:00:00

  • Understanding brain penetrance of anticancer drugs.

    abstract::This paper explicates the impact of tumor capillary permeability for glioma World Health Organization (WHO) grades II to IV on brain-penetrant drug entry and distribution within the tumor and the brain adjacent to tumor (leading edge). In addition, we consider the distribution of non-brain penetrant drugs and how, in ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noy018

    authors: Levin VA,Ellingson BM

    更新日期:2018-04-09 00:00:00

  • Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma.

    abstract::Identification of the epidermal growth factor receptor variant III (EGFRvIII) mutation in glioblastoma has become increasingly relevant in the optimization of therapy. Traditionally, determination of tumor EGFRvIII-expression has relied on tissue-based diagnostics. Here, we assess the accuracy of magnetic resonance pe...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nos073

    authors: Tykocinski ES,Grant RA,Kapoor GS,Krejza J,Bohman LE,Gocke TA,Chawla S,Halpern CH,Lopinto J,Melhem ER,O'Rourke DM

    更新日期:2012-05-01 00:00:00

  • HDAC inhibition induces expression of scaffolding proteins critical for tumor progression in pediatric glioma: focus on EBP50 and IRSp53.

    abstract:BACKGROUND:Diffuse midline glioma (DMG) is a pediatric malignancy with poor prognosis. Most children die less than one year after diagnosis. Recently, mutations in histone H3 have been identified and are believed to be oncogenic drivers. Targeting this epigenetic abnormality using histone deacetylase (HDAC) inhibitors ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noz215

    authors: Capdevielle C,Desplat A,Charpentier J,Sagliocco F,Thiebaud P,Thézé N,Fédou S,Hooks KB,Silvestri R,Guyonnet-Duperat V,Petrel M,Raymond AA,Dupuy JW,Grosset CF,Hagedorn M

    更新日期:2020-04-15 00:00:00

  • A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool.

    abstract:BACKGROUND:Glioblastoma multiforme (GBM) is the most frequent malignant brain tumor in adults, and its prognosis remains dismal despite intensive research and therapeutic advances. Diagnostic biomarkers would be clinically meaningful to allow for early detection of the tumor and for those cases in which surgery is cont...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not218

    authors: Manterola L,Guruceaga E,Gállego Pérez-Larraya J,González-Huarriz M,Jauregui P,Tejada S,Diez-Valle R,Segura V,Samprón N,Barrena C,Ruiz I,Agirre A,Ayuso A,Rodríguez J,González A,Xipell E,Matheu A,López de Munain A,Tuñón

    更新日期:2014-04-01 00:00:00

  • Rhenium-186 liposomes as convection-enhanced nanoparticle brachytherapy for treatment of glioblastoma.

    abstract::Although external beam radiation is an essential component to the current standard treatment of primary brain tumors, its application is limited by toxicity at doses more than 80 Gy. Recent studies have suggested that brachytherapy with liposomally encapsulated radionuclides may be of benefit, and we have reported met...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nos060

    authors: Phillips WT,Goins B,Bao A,Vargas D,Guttierez JE,Trevino A,Miller JR,Henry J,Zuniga R,Vecil G,Brenner AJ

    更新日期:2012-04-01 00:00:00

  • Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease.

    abstract::Glioblastoma multiforme (GBM) is a lethal primary malignant brain tumor in adults. R115777 (tipifarnib) is an oral agent with antiproliferative effects, being a potent and selective inhibitor of farnesyltransferase. This multicenter, open-label phase II study was designed to evaluate the efficacy and safety of R115777...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1215/15228517-2008-070

    authors: Lustig R,Mikkelsen T,Lesser G,Grossman S,Ye X,Desideri S,Fisher J,Wright J,New Approaches to Brain Tumor Therapy CNS Consortium.

    更新日期:2008-12-01 00:00:00

  • Assessment and treatment relevance in elderly glioblastoma patients.

    abstract::Glioblastoma (GBM) is the most common malignant primary brain tumor. Its incidence continues to increase in the elderly because the older segment of the population is growing faster than any other age group. Most clinical studies exclude elderly patients, and "standards of care" do not exist for GBM patients aged >70 ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nou063

    authors: Bauchet L,Zouaoui S,Darlix A,Menjot de Champfleur N,Ferreira E,Fabbro M,Kerr C,Taillandier L

    更新日期:2014-11-01 00:00:00

  • BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma.

    abstract:BACKGROUND:Nonfunctioning pituitary adenoma (NFPA) and growth hormone pituitary adenoma (GHPA) are major subtypes of pituitary adenomas (PAs). The primary treatment is surgical resection. However, radical excision remains challenging, and few effective medical therapies are available. It is urgent to find novel targets...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noaa084

    authors: Shi C,Ye Z,Han J,Ye X,Lu W,Ji C,Li Z,Ma Z,Zhang Q,Zhang Y,He W,Chen Z,Cao X,Shou X,Zhou X,Wang Y,Zhang Z,Li Y,Ye H,He M,Chen H,Cheng H,Sun J,Cai J,Huang C,Ye F,Luo C,Zhou B,Ding H,Zhao Y

    更新日期:2020-08-17 00:00:00

  • Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha.

    abstract:Background:The mesenchymal phenotype in glioblastoma (GBM) and other cancers drives aggressiveness and treatment resistance, leading to therapeutic failure and recurrence of disease. Currently, there is no successful treatment option available against the mesenchymal phenotype. Methods:We classified patient-derived GB...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nox119

    authors: Olmez I,Love S,Xiao A,Manigat L,Randolph P,McKenna BD,Neal BP,Boroda S,Li M,Brenneman B,Abounader R,Floyd D,Lee J,Nakano I,Godlewski J,Bronisz A,Sulman EP,Mayo M,Gioeli D,Weber M,Harris TE,Purow B

    更新日期:2018-01-22 00:00:00

  • Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma.

    abstract:Background:Sonidegib (LDE225) is a potent, selective hedgehog (Hh) inhibitor of Smoothened. This study explored the safety and pharmacokinetics of sonidegib in children with relapsed/recurrent tumors followed by a phase II trial in pediatric and adult patients with relapsed medulloblastoma (MB) to assess tumor response...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nox109

    authors: Kieran MW,Chisholm J,Casanova M,Brandes AA,Aerts I,Bouffet E,Bailey S,Leary S,MacDonald TJ,Mechinaud F,Cohen KJ,Riccardi R,Mason W,Hargrave D,Kalambakas S,Deshpande P,Tai F,Hurh E,Geoerger B

    更新日期:2017-10-19 00:00:00

  • New concepts in the management of diffuse low-grade glioma: Proposal of a multistage and individualized therapeutic approach.

    abstract::Diffuse low-grade glioma grows, migrates along white matter tracts, and progresses to high-grade glioma. Rather than a "wait and see" policy, an aggressive attitude is now recommended, with early surgery as the first therapy. Intraoperative mapping, with maximal resection according to functional boundaries, is associa...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nou153

    authors: Duffau H,Taillandier L

    更新日期:2015-03-01 00:00:00

  • Racial differences in primary central nervous system lymphoma incidence and survival rates.

    abstract::To determine racial and ethnic differences in incidence and survival in patients with primary central nervous system lymphoma (PCNSL), NCI Surveillance, Epidemiology, and End Results (SEER) program data from 1992 to 2002 were queried. Data were substratified by age (20-49 years vs. 50 or above) and race (White, Black,...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2008-103

    authors: Pulido JS,Vierkant RA,Olson JE,Abrey L,Schiff D,O'Neill BP

    更新日期:2009-06-01 00:00:00

  • Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study.

    abstract::The purpose of this study was to determine the dose-limiting toxicities, maximum tolerated dose, pharmacokinetics, and intratumor and brain distribution of motexafin gadolinium (MGd) with involved field radiation therapy in children with newly diagnosed intrinsic pontine gliomas. MGd was administered as a 5-min intrav...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2008-043

    authors: Bradley KA,Pollack IF,Reid JM,Adamson PC,Ames MM,Vezina G,Blaney S,Ivy P,Zhou T,Krailo M,Reaman G,Mehta MP,Children's Oncology Group.

    更新日期:2008-10-01 00:00:00

  • Brain cancer mortality in the United States, 1986 to 1995: a geographic analysis.

    abstract::The Atlas of Cancer Mortality in the United States, 1950-94 (Devesa et al.) published in 1999 by the National Institutes of Health suggests that there are elevated rates of brain and other nervous system cancer in the northwestern, north central, and southeastern parts of the country. Being descriptive in nature, the ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/S1152851703000450

    authors: Fang Z,Kulldorff M,Gregorio DI

    更新日期:2004-07-01 00:00:00

  • MRI contrast agent for targeting glioma: interleukin-13 labeled liposome encapsulating gadolinium-DTPA.

    abstract:BACKGROUND:Detection of glioma with MRI contrast agent is limited to cases in which the blood-brain barrier (BBB) is compromised as contrast agents cannot cross the BBB. Thus, an early-stage infiltrating tumor is not detectable. Interleukin-13 receptor alpha 2 (IL-13Rα2), which has been shown to be overexpressed in gli...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nov263

    authors: Liu X,Madhankumar AB,Miller PA,Duck KA,Hafenstein S,Rizk E,Slagle-Webb B,Sheehan JM,Connor JR,Yang QX

    更新日期:2016-05-01 00:00:00

  • Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas.

    abstract::We have previously demonstrated that chordomas express activated platelet-derived growth factor receptor (PDGFRB) and that treatment with imatinib, which is capable of switching off the activation of various receptor tyrosine kinases (RTKs) including PDGFRB, benefits a number of patients. The aim of this study was to ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noq003

    authors: Tamborini E,Virdis E,Negri T,Orsenigo M,Brich S,Conca E,Gronchi A,Stacchiotti S,Manenti G,Casali PG,Pierotti MA,Pilotti S

    更新日期:2010-08-01 00:00:00

  • The role of pericytes in blood-vessel formation and maintenance.

    abstract::Blood vessels are composed of two interacting cell types. Endothelial cells form the inner lining of the vessel wall, and perivascular cells--referred to as pericytes, vascular smooth muscle cells or mural cells--envelop the surface of the vascular tube. Over the last decades, studies of blood vessels have concentrate...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1215/S1152851705000232

    authors: Bergers G,Song S

    更新日期:2005-10-01 00:00:00

  • Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

    abstract::People with neurofibromatosis 1 (NF1) have multiple benign neurofibromas and a 10% lifetime risk of developing malignant peripheral nerve sheath tumors (MPNSTs). Most MPNSTs develop from benign plexiform neurofibromas, so the burden of benign tumors may be a risk factor for developing MPNST. We studied 13 NF1 patients...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2008-011

    authors: Mautner VF,Asuagbor FA,Dombi E,Fünsterer C,Kluwe L,Wenzel R,Widemann BC,Friedman JM

    更新日期:2008-08-01 00:00:00

  • Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report.

    abstract::This study estimated the maximum tolerated dose (MTD) of imatinib with irradiation in children with newly diagnosed brainstem gliomas, and those with recurrent malignant intracranial gliomas, stratified according to use of enzyme-inducing anticonvulsant drugs (EIACDs). In the brainstem glioma stratum, imatinib was ini...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2006-031

    authors: Pollack IF,Jakacki RI,Blaney SM,Hancock ML,Kieran MW,Phillips P,Kun LE,Friedman H,Packer R,Banerjee A,Geyer JR,Goldman S,Poussaint TY,Krasin MJ,Wang Y,Hayes M,Murgo A,Weiner S,Boyett JM

    更新日期:2007-04-01 00:00:00

  • Posttranscriptional deregulation of signaling pathways in meningioma subtypes by differential expression of miRNAs.

    abstract:BACKGROUND:Micro (mi)RNAs are key regulators of gene expression and offer themselves as biomarkers for cancer development and progression. Meningioma is one of the most frequent primary intracranial tumors. As of yet, there are limited data on the role of miRNAs in meningioma of different histological subtypes and the ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nov014

    authors: Ludwig N,Kim YJ,Mueller SC,Backes C,Werner TV,Galata V,Sartorius E,Bohle RM,Keller A,Meese E

    更新日期:2015-09-01 00:00:00

  • Molecular and translational advances in meningiomas.

    abstract::Meningiomas are the most common primary intracranial neoplasm. The current World Health Organization (WHO) classification categorizes meningiomas based on histopathological features, but emerging molecular data demonstrate the importance of genomic and epigenomic factors in the clinical behavior of these tumors. Treat...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/noy178

    authors: Suppiah S,Nassiri F,Bi WL,Dunn IF,Hanemann CO,Horbinski CM,Hashizume R,James CD,Mawrin C,Noushmehr H,Perry A,Sahm F,Sloan A,Von Deimling A,Wen PY,Aldape K,Zadeh G,International Consortium on Meningiomas.

    更新日期:2019-01-14 00:00:00

  • Arterial spin labeling MR imaging for differentiation between high- and low-grade glioma-a meta-analysis.

    abstract:Background:Arterial spin labeling is an MR imaging technique that measures cerebral blood flow (CBF) non-invasively. The aim of the study is to assess the diagnostic performance of arterial spin labeling (ASL) MR imaging for differentiation between high-grade glioma and low-grade glioma. Methods:Cochrane Library, Emba...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,meta分析

    doi:10.1093/neuonc/noy095

    authors: Falk Delgado A,De Luca F,van Westen D,Falk Delgado A

    更新日期:2018-10-09 00:00:00

  • Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts.

    abstract::Development of model systems that recapitulate the molecular heterogeneity observed among glioblastoma multiforme (GBM) tumors will expedite the testing of targeted molecular therapeutic strategies for GBM treatment. In this study, we profiled DNA copy number and mRNA expression in 21 independent GBM tumor lines maint...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2008-113

    authors: Hodgson JG,Yeh RF,Ray A,Wang NJ,Smirnov I,Yu M,Hariono S,Silber J,Feiler HS,Gray JW,Spellman PT,Vandenberg SR,Berger MS,James CD

    更新日期:2009-10-01 00:00:00

  • High-dose methotrexate is beneficial in parenchymal brain masses of uncertain origin suspicious for primary CNS lymphoma.

    abstract::In patients with parenchymal brain masses of uncertain origin responsive to corticosteroids, primary CNS lymphoma (PCNSL) should be considered. PCNSL is a rare but aggressive brain tumor that is highly sensitive to high-dose methotrexate (HDMTX)-based chemotherapy. We report a series of six patients with brain masses ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2006-037

    authors: Kiewe P,Loddenkemper C,Anagnostopoulos I,Reinwald M,Thiel E,Korfel A

    更新日期:2007-04-01 00:00:00

  • Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis.

    abstract:BACKGROUND:The Cancer Genome Atlas (TCGA) project is a large-scale effort with the goal of identifying novel molecular aberrations in glioblastoma (GBM). METHODS:Here, we describe an in-depth analysis of gene expression data and copy number aberration (CNA) data to classify GBMs into prognostic groups to determine cor...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not024

    authors: Kim YW,Koul D,Kim SH,Lucio-Eterovic AK,Freire PR,Yao J,Wang J,Almeida JS,Aldape K,Yung WK

    更新日期:2013-07-01 00:00:00

  • Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas.

    abstract::The majority of meningiomas are probably benign but a number of tumors display considerable histological and/or clinical aggressivity, sometimes with unexpectedly high recurrence rates after radical removal. Understanding the potential behavior of these tumors in individual patients is critical for rational therapeuti...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noq081

    authors: Pérez-Magán E,Rodríguez de Lope A,Ribalta T,Ruano Y,Campos-Martín Y,Pérez-Bautista G,García JF,García-Claver A,Fiaño C,Hernández-Moneo JL,Mollejo M,Meléndez B

    更新日期:2010-12-01 00:00:00

  • Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children.

    abstract::We conducted a single-arm phase II study to evaluate the efficacy and safety of radiotherapy combined with 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine (TPDCV) chemotherapy for treating malignant astrocytoma in children and anaplastic ependymoma in patients of all ages. Between 1984 and 199...

    journal_title:Neuro-oncology

    pub_type: 临床试验,杂志文章

    doi:10.1093/neuonc/2.1.22

    authors: Levin VA,Lamborn K,Wara W,Davis R,Edwards M,Rabbitt J,Malec M,Prados MD

    更新日期:2000-01-01 00:00:00

  • Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme.

    abstract::Glioblastoma multiforme (GBM) continues to be a difficult therapeutic challenge. Our study was conducted to determine whether improved survival and tumor control could be achieved with modern delivery of fast neutron radiation using three-dimensional treatment planning. Ten patients were enrolled. Eligibility criteria...

    journal_title:Neuro-oncology

    pub_type: 临床试验,杂志文章

    doi:10.1215/15228517-2007-044

    authors: Stelzer KJ,Douglas JG,Mankoff DA,Silbergeld DL,Krohn KA,Laramore GE,Spence AM

    更新日期:2008-02-01 00:00:00